Pharmaceutical industry faces challenges with drug solubility

The pharmaceutical industry is facing significant technical challenges regarding drug solubility, with reports indicating that 70% to 90% of new chemical active ingredients under development exhibit poor water solubility. This trend is driving growth in the pharmaceutical carrier and solubilizer markets, which are projected to see annual growth rates of approximately 5.8% to 6.2% through 2035.

To address these challenges, specialized excipients and formulation technologies are becoming increasingly critical for ensuring drug stability and controlled release. For instance, Betamethasone-17,21-dipropionate requires a purity level of at least 99.5% to meet quality standards. Companies like Fette Compacting and Sotax are collaborating to support manufacturers of solid oral dosage forms by integrating tableting, processing, and analytical development.

In the sector of active pharmaceutical ingredients (APIs), companies such as NHU are highlighting diverse portfolios including vitamins, ibuprofen, and chemical intermediates. Their ibuprofen products meet various international pharmacopoeia standards, including EP, USP, and JP, offering a range of particle sizes to meet specific manufacturing needs.